Home : Unsafe Drugs : Cimzia : Newsfeeds

Cimzia - Newsfeeds

XOMA Announces Presentation And Webcast At NewsMakers In The Biotech Industry Conference: including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease.
Enbrel, Humira and Remicade Will Lose Patient Share Through 2013, According to a New Report from ...: BURLINGTON, Mass. , Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, between 2010 and 2013, surveyed European rheumatologists expect well-established TNF-al
Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohn's Disease to be Highlighted ...: CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for ...
XOMA 052 Phase 2a Trial Enrollment Completed: including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. The company has a premier antibody discovery and development platform that incorporates ...
Navy airdrops dead, drugged mice in battle with snake species: ... to sweep it under the carpet the u$ probably spent the 1st 10 years ... and happy snakes. A king snake species would be a safer alternative. They would eat the brown snake, and other snakes. They prefer snakes to rodents and are non venomous. Most ...
XOMA Announces Presentation and Webcast at BIO Investor Forum: including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. The company has a premier antibody discovery and development platform that incorporates ...
Despite Dramatic Changes, the Crohn's Disease Drug Market Will Experience Only Moderate Growth Through ...: one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth ... available on commercially significant disease topics. About Decision Resources ...
Russia's Rheumatoid Arthritis Drug Market will Reach Over $470 Million by 2014: ... Emerging Markets report entitled Rheumatoid Arthritis in Russia also finds that two agents expected to launch by the end of the 2009 - 2014 forecast period -- Merck's Simponi and UCB's Cimzia -- in addition to Pfizer's Enbrel and Bristol-Myers Squibb ...
RAPID and FAST4WARD Trials: Certolizumab Pegol for Rheumatoid Arthritis: Cimzia certolizumab pegol – European Public Assessment Report for the Public www.ema.europa.eu/humandocs/PDFs/EPAR/cimzia/H-1037-en1.pdf (Accessed 27 March 2010)
Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment: The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira® and Remicade ® utilized in the treatment of Crohn's Disease , and the subsequent development of ...

Prometheus, Tarrot to Seek Crohn's Disease Biomarkers for PGx Applications: The deal covers genetic and serologic biomarkers as predictors of response to drugs such as Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab). Diagnostic tests would be developed from the biomarkers. Under the terms of the deal,
DEALTALK-Savient's gout drug nod may trigger bid war: BR ) Cimzia, Amgen and Pfizer's Enbrel and J&J's Simponi and Remicade. East Brunswick, New Jersey-based Savient sees a patient population of about 170,000, while the U.S. health regulator estimates there are about 90,000 patients with this indication. (
Canon Communications' 2011 Medical Design Excellence Awards Calls for Entries: manufacturing ... American Institute for Medical and Biological Engineering; Human Factors and Ergonomics Society; Medical Device Manufacturers Association; and National Collegiate Inventors and Innovators Alliance. Canon Communications LLC, a portfolio ...
Nektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference: including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.
Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF ...: ... markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira ... data analysis and modeling will be utilized to create new discoveries in this area of pharmacogenomics. We are pleased to be working with Prometheus,
Research and Markets: Commercial Insight: Inflammatory Bowel Disease - Future Market Prospects ...: Cimzia and 5-aminosalicylates, such as Lialda Insight and analysis of the strategies of the key developers in the IBD market Highlights of this title Leading on from the SONIC study, experts would like to treat IBD ...
FastMoneyTalk.com: Top Pharmaceutical Stock Picks: PINKSHEETS: AXXE & NASDAQ: XOMAD: including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. The company has a premier antibody discovery and ...
TNF inhibitors offer relief to arthritis sufferers: market: etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), golimumab (Simponi) and certolizumab (Cimzia). About one-third of people with rheumatoid arthritis are probably on a TNF drug or have been on ...
XOMA Regains NASDAQ Compliance: including LUCENTIS(R) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(R) (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. The company has a premier antibody discovery and ...
Research and Markets: Commercial Insight: Inflammatory Bowel Disease - Future Market Prospects ...: Cimzia and 5-aminosalicylates, such as Lialda Insight and analysis of the strategies of the key developers in the IBD market Highlights of this title Leading on from the SONIC study, experts would like to treat IBD ...

Looking for a Washington, DC Cimzia lawyer? Get in touch with one of our Washington, DC Cimzia lawyers now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: Previous 1 2 3 4 5 6 7 8 9 10 11 ... Next

Need A Cimzia Attorney?

First Name Last Name Email Address State

Legal Issue

Unsafe Drugs: Cimzia Click to select a Legal Issue

Was Your Health Negatively Affected?

Please Describe the Injury

close this window

Cimzia Information

Click to View Our Legal Resources

Looking for a Washington, DC Cimzia lawyer? Get in touch with one of our Washington, DC Cimzia lawyers now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120517-012520

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

Unsafe Drugs: Cimzia Click to select a Legal Issue

Close (x)

Find Legal Help for Your Cimzia Case - Submit Your Information Below

Do you need legal assistance with your Cimzia case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * Unsafe Drugs: Cimzia Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.